Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

3.94 EUR

+3.41 %

5,643 following
Corporate customer

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+3.41 %
+7.36 %
+4.51 %
+0.38 %
-9.74 %
-4.95 %
-12.05 %
-39.76 %
-13.97 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
84.53M EUR
Turnover
278.69K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Buy
Target price
Updated
17.12.2025
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.2.
2026

Annual report '25

6.5.
2026

Interim report Q1'26

8.5.
2026

General meeting '26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
“Optomed’s Aurora AEYE achieved 1,200 U.S. deployments by December 2025, winning 8% of diabetic-retinopathy screens formerly managed by tabletop devices.” Source: Ophthalmology Diagnostics Market Report | Industry Analysis, Size & Forecast Overview That figure can’t possibly be correct...
yesterday
by Juha Kinnunen
43
Updated today: Aurora IQ is included in a new retinopathy-related study. Fundus images are taken and analyzed using an AI algorithm. Fundus images are captured with two devices: a fixed fundus camera (CenterVue DRSplus) and the Optomed Aurora IQ handheld fundus camera. Retinal images...
yesterday
by Koukku
20
At first glance, this appears to be University Hospital Tuebingen’s own study, which is unlikely to be linked to either company’s FDA applications. No other sponsors or partners are visible (not Revenio, Optomed, or a CRO). So, it may be that they are simply using Revenio’s and Optomed...
yesterday
by Juha Kinnunen
15
Looks like the CEO of Ophthalytics Inc has also switched from their day job to full-time entrepreneurship: linkedin.com #ai #blindness #blindnessprevention #grateful #newchapter #aiinhealthcare... After 10 meaningful years, today marks my last day at GE. I’m deeply grateful for the...
yesterday
by Mr. Stock
9
It is indeed the University of Tübingen’s own research. The university has developed its own AI model, which was released in May 2025. The model is generalized. Public image data was used for its development. In total, more than 30,000 images were used. This means the images were...
yesterday
by j.sälli
8
El Jefe’s quote from the neighbor: A joint study with Revenio (this is what I just mentioned). Their operations would fit well together in other ways too.
yesterday
by Koukku
5
Yeah, the algorithm must have been developed using Aurora IQ camera images, or at least fine-tuned, so the process could have been underway for a long time already. For Lumo, according to the last interim report, the dataset was already being collected then, and likely even earlier...
yesterday
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.